Key facts
- Enhanced Genomics’s last known valuation is $28.1M (Sep 2025).
- It has raised $21.8M; the latest was Later Stage VC ($19.0M) in Sep 2025.
- Notable investors include BGF (Financial Services), Parkwalk Advisors, Meltwind Advisory, Jonathan Milner, Vincent Tchenguiz — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Enhanced Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Enhanced Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enhanced Genomics
Developer of a biotechnology platform designed to develop tools for large-scale analysis of genetic variations and gene function. The company's technology specializes in profiles of three-dimensional genome folding at high resolution for all genes and their enhancers simultaneously, enabling researchers to focus on the advancement of novel drugs in areas of unmet medical needs.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 24
- Website
- enhancedgenomics.com/
- Ownership
- Privately Held (backing)
Enhanced Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enhanced Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enhanced Genomics in its N-PORT filings yet. We sweep new filings monthly.